
Danish pharmaceutical company Lundbeck may being subjected to a series of compensation claims after losing an appeal case at the European Court of Justice on Thursday.
So estimates Senior Equity Analyst Søren Løntoft Hansen from the Danish bank Sydbank.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app